Methods: Sera from children (n=20) and adults (n=3) with biopsy-diagnosed EoE were obtained and analyzed for periostin (Periostin/OSF-2 (human), Phoenix Pharmaceuticals, Inc.) and TARC (human CCL-17 (TARC), BioLegend, Inc.) by ELISA.
Results: Mean periostin level (ng/mL) (n=23, range=10.3-405.5, mean±SEM= 186.7±23.2) was significantly higher than reported levels for healthy controls and was higher in patients with signs of fibrosis (esophageal narrowing, mucosal rings, and longitudinal furrows) (n=13, mean±SEM= 204.2±35.69) versus without signs of fibrosis (n=10, mean±SEM= 163.9±26.87). Mean TARC level (pg/mL) (n=23, range=88.4-1159, mean±SEM= 511.8±64.06) was significantly higher than reported levels for healthy controls and was higher in patients with signs of fibrosis (n=11, mean±SEM= 626.3±93.59) versus without signs of fibrosis (n=12, mean±SEM= 407.0±79.63). In addition, changes in periostin and TARC levels in individual patients’ sera taken at different time points vary with alterations in their clinicopathologic status.
Conclusions: Our results indicate that periostin and TARC levels are elevated in EoE patients and in the subset presenting with fibrosis. Changes in these levels also correlate with changes in clinicopathologic status, suggesting they are reflective of disease activity and, therefore, look promising as biomarkers for EoE.